Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04727489

Study of the Genetic Factors Involved in Autism and Related Disorders

The main objective of the study is to define, for Autism Spectrum Disorder, the extent of genetic variation in synaptic pathways that may be targeted for therapeutic development. For this purpose the investigators will take advantage of large, well-characterized cohorts of patients with Autism Spectrum Disorder for genetic screenings. Targeted sequencing of selected synaptic genes, previously associated with Autism Spectrum Disorder, will be carried out in these cohorts with deep coverage of coding regions and a strong focus on previously untested regulatory regions. Genomic data from Copy Number Variant, whole genome sequencing and exome sequencing, available for some of these patients, will be integrated in the overall analysis. The investigators will strongly emphasize the establishment of comprehensive genotype/phenotype correlations.

Recruiting

Interested in participating?

Request Info

Key information

Age range

24 month–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre de rehabilitation psychosociale, Hopital Saint Egreve, Grenoble, France

Loading trial locations.

About this study

Aim 1: To identify genetic variants in selected synaptic genes, by targeted sequencing with deep coverage of coding regions and a strong focus on previously untested regulatory regions in Autism Spectrum Disorder

Aim 2: To define the range of clinical phenotypes caused by mutations in synaptic genes by establishing detailed genotype/phenotype correlations and analyzing segregation in families with multiple individuals affected by Autism Spectrum Disorder, Autism Spectrum Disorder traits or other neuropsychiatric disorders

Aim 3: To identify the neuronal phenotypes caused by deleterious synaptic mutations for further translational studies

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

---------------------------------------------------------------------------------------------------

Probands with Autism Spectrum Disorder

  • Meet the diagnostic criteria for ASD of the DSM-5 [American Psychiatric Association, 2013] based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Rutter et al, 2003) and those of the Autism Diagnosis Observation Schedule (ADOS-2) (Lord et al, 2012)
  • Be at least 24 months (no upper age limit)
  • Somatic and Intellectual state compatible with a blood test
  • Affiliation to the social insurance
  • Signature of informed consent by the applicant or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Controls without ASD

  • At least 24 months old
  • Somatic and Intellectual state compatible with a blood test
  • Affiliation to the social insurance
  • Signature of informed consent by the subject or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Relatives of the probands with ASD or of controls without ASD

  • At least 24 months old
  • Somatic and Intellectual state compatible with a blood test
  • Affiliation to the social insurance
  • Signature of informed consent by the subject or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Exclusion criteria

--------------------------------------------------------------------------------------------------

Probands with Autism Spectrum Disorder

  • Severe Intelectual Deficiency (IQ,35 or developmental age <18 months)

●. Personal psychiatric history (schizophrenia, bipolar disorder, substance use disorder (except tobacco), recurrent depression disorder, severe instable anxiety disorder)

  • Personal neurologic history (epilepsy, or severe neurological disease)

Relatives of the probands with ASD, of the controls or the controls:

● Medical condition (psychiatric or somatic) not compatible with the inclusion

Treatment and study plan

DNA from subjects will be stored in the biobank of our study.

Genetic

Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.

Other names: diagnostic test

Primary outcomes

  1. Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder

    Time frame: up to 12 months after completion of the inclusion and molecular explorations

    Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder

Secondary outcomes

  1. Prevalence of the deleterious mutations in the major biological pathways in Autism Spectrum Disorder

    Time frame: up to 12 months after completion of the inclusion and molecular explorations

    The deleterious mutations that the investigators will identify in genes related to Autism Spectrum Disorders will help to have a comprehensive framework of biological pathways involved in Autism Spectrum Disorder

Study contacts

Contact information is provided by the study sponsor or research team.

Marion Leboyer, M.D, Ph.D

CONTACT

[email protected]

+33149813131

Richard Delorme, M.D, Ph.D

CONTACT

[email protected]

+33662725334

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Acronym: Gene&autism

Important dates

Study start
2021
Primary completion
2036
Study completion
2036
First posted
Jan 27, 2021
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.